LYRFIGTU
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
POST_ANCHOR_TAIL: Issued crystalline/XRPD-limited lirafugratinib claims remain after the 2040 substance anchor. The structurally different US12522605 is excluded from both the target anchor and target tail.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| US11780845 | 2040-05-12 | CLAIM_REVIEW_NOT_EXACT_OB_LISTING — | Y | N | TRUE_DS Issued claim 1 expressly claims the lirafugratinib free-compound structure or a pharmaceutically acceptable salt; the chemical graphic matches FDA section 11, including the 4-amino pyrrolo[2,3-d]pyrimidine core, fluoro-phenoxy-methylpyrimidine substituent, N7 methyl and methacrylamide. Grant front shows zero PTA and no disclosed terminal-disclaimer notice. First nonprovisional PCT filing 2020-05-12 gives 2040-05-12. US12522605 was recovered in full: both independent claims 1 and 5 require a different ring core with a mandatory carbonyl (grant columns 1973 and 1977); every other issued claim depends on these claims, so its 633-day PTA/2042-02-04 term is not a target substance anchor. US12152034 is crystal/XRPD-limited OTHER, not TRUE_DS; its 2041-11-18 term remains a later tail. US20260138983 is pending and is not an issued right. No unawarded PTE or pediatric extension is added. | — | — | — |
| US12152034 | 2041-11-18 | CLAIM_REVIEW_NOT_EXACT_OB_LISTING — | N | N | OTHER_CRYSTAL Issued crystalline/XRPD-limited lirafugratinib claims remain after the 2040 substance anchor. The structurally different US12522605 is excluded from both the target anchor and target tail. | — | — | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| No exclusivity facts are recorded in this product snapshot. | ||||||||
2026-10-13 · NO_REGULATORY_EXCLUSIVITY_IDENTIFIED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED
2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| No generic approval facts are linked to this product. | |||||||
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 0 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No final-approval records are linked to this product. | ||||||
Decision evidence (3)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PATENT | 2040-05-12 | CANONICAL_ANCHOR | Issued claim 1 expressly claims the lirafugratinib free-compound structure or a pharmaceutically acceptable salt; the chemical graphic matches FDA section 11, including the 4-amino pyrrolo[2,3-d]pyrimidine core, fluoro-phenoxy-methylpyrimidine substituent, N7 methyl and methacrylamide. Grant front shows zero PTA and no disclosed terminal-disclaimer notice. First nonprovisional PCT filing 2020-05-12 gives 2040-05-12. US12522605 was recovered in full: both independent claims 1 and 5 require a different ring core with a mandatory carbonyl (grant columns 1973 and 1977); every other issued claim depends on these claims, so its 633-day PTA/2042-02-04 term is not a target substance anchor. US12152034 is crystal/XRPD-limited OTHER, not TRUE_DS; its 2041-11-18 term remains a later tail. US20260138983 is pending and is not an issued right. No unawarded PTE or pediatric extension is added. | Source |
| PATENT | 2041-11-18 | FTO_TAIL | Issued crystalline/XRPD-limited lirafugratinib claims remain after the 2040 substance anchor. The structurally different US12522605 is excluded from both the target anchor and target tail. | Source |
| REGULATORY_STATUS | 2040-05-12 | CANONICAL_DECISION | POST_ANCHOR_TAIL: Issued crystalline/XRPD-limited lirafugratinib claims remain after the 2040 substance anchor. The structurally different US12522605 is excluded from both the target anchor and target tail. | Source |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.